Search
Glaukos Corp
GKOSAdd to Watchlist
144.420USD
0.0000.00%
Close 06/26, 16:00（ET）Quotes delayed by 15 min
8.43BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
+10.51%
1 Month
+25.62%
6 Months
+24.28%
Year to Date
+27.91%
1 Year
+42.91%
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
290.59P/E Dynamic
--Dividend TTM
3.41%Turnover Ratio
144.420Prev. Close
0.000Low
0.00Turnover
LossP/E Static
12.56P/B
0.00%Div Yield TTM
-20.36%ROA
148.11052wk High
2.56Volume Ratio
-146.37MNet Profit
58.36MShares
-3.3024EPS TTM
0.86Beta
-26.39%ROE
73.16052wk Low
2.87%Amplitude
77.86%Gross Margin
8.43BMarket Cap
11.61Reward/Risk
2.91%Risk Rate
TradingKey Stock Score of Glaukos Corp
Currency: USD Updated: 2026-06-26Key Insights
Glaukos Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 4 out of 203 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 158.33.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Glaukos Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
Glaukos Corp Highlights
StrengthsRisks
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 61.24% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 507.44M.
Fairly Valued
The company’s latest PE is -43.73, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 59.35M shares, decreasing 4.48% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 25.85K shares of this stock.
Analyst Rating
Based on
15
analysts
Buy
Current Rating
158.333
Target Price
+11.06%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Glaukos Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Glaukos Corp Info
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Ticker SymbolGKOS
CompanyGlaukos Corp
CEOBurns (Thomas William)
Websitehttps://www.glaukos.com
Related Instruments
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%Popular Instruments
FAQs
What is the current price of Glaukos Corp (GKOS)?
The current price of Glaukos Corp (GKOS) is 144.42.
What is the symbol of Glaukos Corp?
The ticker symbol of Glaukos Corp is GKOS.
What is the 52-week high of Glaukos Corp?
The 52-week high of Glaukos Corp is 148.11.
What is the 52-week low of Glaukos Corp?
The 52-week low of Glaukos Corp is 73.16.
What is the market capitalization of Glaukos Corp?
The market capitalization of Glaukos Corp is 8.48B.
Is Glaukos Corp (GKOS) currently rated as Buy, Hold, or Sell?
According to analysts, Glaukos Corp (GKOS) has an overall rating of Buy, with a price target of 158.33.
What is the Earnings Per Share (EPS TTM) of Glaukos Corp (GKOS)?
The Earnings Per Share (EPS TTM) of Glaukos Corp (GKOS) is -3.28.
